EUCTR2009-011020-65-FR进行中（未招募）1 期
A phase III study of lenalidomide maintenance after debulking with gemcitabine or liposomal doxorubicin +/- radiotherapy in patients with advanced cutaneous T-cell lymphoma not previously treated with intravenous chemotherapy.
European Organisation for Research and Treatment of Cancer0 个研究点目标入组 30 人开始时间: 2010年1月19日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •- Mycosis Fungoides, Stage IIB to IV or Sézary Syndrome.
- •- Partial or complete response to a specific debulking regimen consisting of either gemcitabine or liposomal doxorubicin no more than 6 weeks prior to randomization. It is acceptable for patients entering the study to have received local radiotherapy for symptom control during the debulking period.
- •- Fit for chemotherapy (adequate organ function, as reflected by creatinine clearance, liver function tests and hematopoietic indices).
- •- Patient informed consent.
- •- WHO Performance status 0-2.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Disease previously treated by intravenous chemotherapy (gemcitabine or caelyx
- •are allowed) used in the debulking regimen.
- •- Disease not appropriate for skin-directed therapy (per local institution standards)
- •- Contraindications to lenalidomide treatment
研究者
相似试验
进行中（未招募）
1 期
A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma.Cutaneous T-cell lymphoma: Mycosis Fungoides, Stage IIB to IV or Sézary SyndromeMedDRA version: 14.1Level: LLTClassification code 10028508Term: Mycosis fungoides/Sezary syndromeSystem Organ Class: 100000004864EUCTR2009-011020-65-DEEuropean Organisation for Research and Treatment of Cancer30
进行中（未招募）
1 期
A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma.Cutaneous T-cell lymphoma: Mycosis Fungoides, Stage IIB to IV or Sézary SyndromeMedDRA version: 14.1 Level: LLT Classification code 10028508 Term: Mycosis fungoides/Sezary syndrome System Organ Class: 100000004864EUCTR2009-011020-65-GBEuropean Organisation for Research and Treatment of Cancer30
撤回
3 期
A phase III study of lenalidomide maintenance after debulking with gemcitabine or liposomal doxorubicin +/- radiotherapy in patients with advanced cutaneous T-cell lymphoma not previously treated with intravenous chemotherapy.Cutaneous lymphomaMycosis Fungoides1002532110040900NL-OMON38396European Organisation for Research in Treatment of Cancer (EORTC)10
进行中（未招募）
不适用
A phase III study of lenalidomide maintenance after debulking with gemcitabine or liposomal doxorubicin +/- radiotherapy in patients with advanced cutaneous T-cell lymphoma not previously treated with intravenous chemotherapy.Cutaneous T-cell lymphoma: Mycosis Fungoides, Stage IIB to IV or Sézary SyndromeMedDRA version: 12.0Level: LLTClassification code 10028508Term: Mycosis fungoides/Sezary syndromeEUCTR2009-011020-65-NLEuropean Organisation for Research and Treatment of Cancer105
进行中（未招募）
1 期
A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma.Cutaneous T-cell lymphoma: Mycosis Fungoides, Stage IIB to IV or Sézary SyndromeMedDRA version: 14.1Level: LLTClassification code 10028508Term: Mycosis fungoides/Sezary syndromeSystem Organ Class: 100000004864EUCTR2009-011020-65-BEEuropean Organisation for Research and Treatment of Cancer105